Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Viatris (NASDAQ:VTRS) through any online brokerage.
Other companies in Viatris’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Viatris has a consensus price target of $17.00.
The stock price for Viatris (NASDAQ: VTRS) is $17.56 last updated October 6, 2026 at 4:32 PM EDT.
There are no upcoming dividends for Viatris.
Viatris does not have any upcoming earnings scheduled.
There is no upcoming split for Viatris.
Viatris is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.